Bilastine is under clinical development by Faes Farma and currently in Phase III for Allergic Conjunctivitis. According to GlobalData, Phase III drugs for Allergic Conjunctivitis have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bilastine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bilastine overview
Bilastine (Bilaxten, Nixar, Alektos, Bilaska, Inorial, Ilaxten, Bitosen, Antires, Ibis, Blexten, Ayrinal, Bilanoa, Obalix, Labixten, Bellozal, Nasitop, Olisir, Allertine, Blaxitec) is a piperidine derivative acts as anti-allergic agent. It is formulated as tablets and solution for oral route and drops solution for ophthalmic route of administration. Bilastine is indicated for the treatment of allergic rhinitis, atopic dermatitis (atopic eczema), chronic urticaria or hives, pruritus, seasonal and perennial allergic conjunctivitis.
Bilastine is under development for the treatment of allergic rhino-conjunctivitis, seasonal allergic rhinitis, recurrent idiopathic angioedema, seasonal allergic conjunctivitis (SAC) or perennial allergic conjunctivitis (PAC).
It was also under development for symptoms of chronic spontaneous urticaria (pruritus, hives).
Faes Farma overview
Faes Farma develops, manufactures, and commercializes pharmaceutical products and raw materials. The company offers prescription drugs, generic drugs, food supplements, over the counter (OTC) medications, baby foods, skin-care treatment products. It exports raw materials and finished pharmaceutical products to pharmaceutical companies worldwide. Faes Farma also owns animal nutrition and healthcare company such as Ingaso farm. The company operates manufacturing and R&D center in Leioa, Spain, laboratory, production plants, subsidiaries, and commercial offices in international markets. The company markets the products in Latin America, Asia, Europe, Africa, and the Middle East. Faes Farma is headquartered in Leioa, Spain.
For a complete picture of Bilastine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
